ALUMIS INC. cotiza a 7.06 USD y tiene una capitalización bursátil de $914M. En los últimos 12 meses ha facturado $7M con un margen de flujo de caja libre del -1539.2%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous sy…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.74 | $-0.25 |
| Estimado | $-0.75 | $-0.71 | $-0.77 | $-0.98 |
| Sorpresa | — | — | +3.9% | +74.5% |
| Métrica | ALMS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -1886.9% | -38.6% | -1848.3% |
| Net Margin | -1011.8% | -33.6% | -978.2% |
| FCF Margin | -1539.2% | -13.9% | -1525.3% |
| ROE | -80.8% | -40.4% | -40.4% |
| ROA | -59.1% | -32.0% | -27.1% |
| Current Ratio | 4.34 | 2.84 | +1.50 |
| Debt / Equity | — | 0.28 | — |